Day: October 13, 2023

Linklogis’ President Ji Kun Was Recognized as Outstanding Young Entrepreneur in the Greater Bay Area

Written by Customer Service on October 13, 2023. Posted in Public Companies.

Hong Kong, China, Oct. 13, 2023 (GLOBE NEWSWIRE) — Recently, the 4th Guangdong-Hong Kong-Macao Greater Bay Area Outstanding Young Entrepreneur Award Ceremony, hosted by the Guangdong-Hong Kong-Macao Bay Area Entrepreneurs Union, was held at the branch venues in Hong Kong, Shenzhen, and Macao. The event was supported by the local governments of Guangdong, Hong Kong, and Macao, the Liaison Offices of the Central People’s Government in Hong Kong Special Administrative Region and Macao Special Administrative Region, major chambers of commerce in Hong Kong and Macao, the Guangdong Federation of Industry and Commerce, and academic institutions. John Lee ka-chiu, Chief Executive of the Hong Kong Special Administrative Region, and Cai Guanshen, member of the Standing Committee of the National Committee of the Chinese People’s...

Invesco Ltd: Form 8.3 – Restaurant group PLC/The RTN – OPD

Written by Customer Service on October 13, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 OPENING POSITION DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1. KEY INFORMATION (a) Full name of discloser: Invesco Ltd. (b) Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree Restaurant Group plc/The RTN (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable...

REVIV3 Procare Company Reports Financial Results for the First Quarter of Fiscal Year 2024

Written by Customer Service on October 13, 2023. Posted in Earnings Releases And Operating Results.

Net Sales (revenue) up 44.1% for the quarter ended August 31, 2023, as compared to the prior year period. Gross Profit (as a percentage of Net Sales) was 76.1% as compared to 77.5% in the prior year period. Operating expenses as a percentage of Net Sales was 73.3% compared to 72.8% in the prior year period.LOS ANGELES, Oct. 13, 2023 (GLOBE NEWSWIRE) — Reviv3 Procare Company (“Reviv3,” “we,” “us,” “our,” or the “Company”) (OTCQB: RVIV), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the first quarter ended August 31, 2023 (“Q1”). “Reviv3 had a strong start to the fiscal year with increased product adoption and customer acquisition through our various sales channels, which resulted...

Form 8.3 – [EMIS Group plc – 12 10 2023] – (CGWL)

Written by Customer Service on October 13, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree EMIS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Form 8.3 – [Instem plc – 12 10 2023] – (CGAML)

Written by Customer Service on October 13, 2023. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree INSTEM PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Progressive Reports September 2023 Results

Written by Customer Service on October 13, 2023. Posted in Earnings Releases And Operating Results.

MAYFIELD VILLAGE, OHIO, Oct. 13, 2023 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for September 2023 and the third quarter of 2023: September Quarter (millions, except per share amounts and ratios; unaudited) 2023 2022 Change 2023 2022 ChangeNet premiums written $4,899.5 $4,007.3 22 % $15,593.8 $13,017.8 20 % Net premiums earned $4,649.3 $3,869.5 20 % $14,894.3 $12,398.9 20 %Net income (loss) $369.3 $(684.4) (154) % $1,121.3 $124.1 NM Per share available to common shareholders $0.62 $(1.17) (153) % $1.89 $0.20 NM Total pretax net realized gains (losses) on securities $(159.1) $(351.0) (55) % $(149.0) $(216.4) (31 )%Combined ratio 89.7 116.2 (26.5) pts. 92.4 99.2 (6.8) pts.Average...

Fortrea Appoints Life Science Executive Dr. John Doyle to Lead Consulting Team

Written by Customer Service on October 13, 2023. Posted in Public Companies.

Industry veteran brings more than three decades of experience spanning R&D, commercialization, and market access DURHAM, N.C., Oct. 13, 2023 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the appointment of John Doyle Dr.P.H., as its new President of Consulting. Doyle will serve on Fortrea’s leadership team and lead a team of consultants and advisors with expertise that spans early development through lifecycle management. “Pharmaceutical and biotechnology innovators must constantly navigate complex and fast-changing business and regulatory environments to achieve their mission,” said Tom Pike, chairman and chief executive officer of Fortrea. “John has extensive industry knowledge and distinctive technical skills that translate to tremendous value for customers....

Balchem Corporation Announces Quarterly Conference Call for Third Quarter Financial Results on October 27, 2023

Written by Customer Service on October 13, 2023. Posted in Public Companies.

MONTVALE, N.J., Oct. 13, 2023 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, October 27th at 11:00 AM Eastern Time (ET) to review third quarter results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Third quarter results will be published prior to the market opening on Friday, October 27, 2023. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call. The conference call will be available for replay two hours after the conclusion of...

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

Written by Customer Service on October 13, 2023. Posted in Public Companies.

Figure 1Six-Month PET ScanFive out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed) Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibody Phase 2 trial screening for na-SPMS to begin in November 2023NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple...

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Written by Customer Service on October 13, 2023. Posted in Public Companies.

IRVINE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the Company will present a poster at the American Society of Nephrology’s upcoming Kidney Week 2023 Annual Meeting taking place in Philadelphia, PA from November 2-5, 2023. The poster will highlight new data from Eledon’s ongoing open-label Phase 1b trial evaluating tegoprubart for the prevention of rejection in kidney transplantation. Details on the poster presentations are below: Title: Tegoprubart for the prevention of rejection in kidney transplant: update of emerging data from an ongoing trialPresenter: Steve Perrin, Ph.D., President and Chief Scientific Officer, Eledon PharmaceuticalsPoster Number: TH-PO835Session Title: Transplantation: Clinical – I [PO2102-1] Session Date and Time: November...

Day: October 13, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice